(FILES) In this file photo taken on August 13, 2021 a health worker prepares a jab of the Pfizer-BioNtech Covid-19 vaccine at the Cau Hansen's Event Center, located in the city of Joinville, state of Santa Catarina, Brazil. - Brazil's health regulator approved the Pfizer-BioNTech Covid-19 vaccine on December 16, 2021 for use in children aged five to 11, clearing the way for the hard-hit country to join the growing list of those extending vaccination to kids. (Photo by Carlos JUNIOR / AFP)
(FILES) In this file photo taken on August 13, 2021 a health worker prepares a jab of the Pfizer-BioNtech Covid-19 vaccine at the Cau Hansen's Event Center, located in the city of Joinville, state of Santa Catarina, Brazil. - Brazil's health regulator approved the Pfizer-BioNTech Covid-19 vaccine on December 16, 2021 for use in children aged five to 11, clearing the way for the hard-hit country to join the growing list of those extending vaccination to kids. (Photo by Carlos JUNIOR / AFP)
/ CARLOS JUNIOR
Por Agencia EFE

La Organización Mundial de la Salud (OMS) pidió hoy no sacar conclusiones apresuradas sobre la efectividad de las actuales vacunas contra el COVID-19 frente a la variante ómicron, pues los datos iniciales que apuntan a una disminución de la protección inmunitaria provienen de estudios de laboratorio y “no de la vida real”.

Conforme a los criterios de

Trust Project
Tipo de trabajo:

NoticiasInformación basada en hechos y verificada de primera mano por el reportero, o reportada y verificada por fuentes expertas.